The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Benign and Malignant Hematologic Diseases Clinical Trial

Official title:

The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03535220
• Other study ID #: 1185686
• Status: Active, not recruiting
• Start date: May 10, 2018
• Est. completion date: January 31, 2025

Study information

• Verified date: May 2018
• Source: American Society of Hematology
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a multicenter, retrospective and prospective, long-term registry of patients with benign or malignant hematologic diseases, whether or not these patients were or were not treated with disease-specific treatments. Information will be collected on patient demographics, disease characteristics, genomic and molecular data, laboratory data, pathology, radiographic reports, clinical status, quality of life, medications, and dosing information. Where appropriate, these data structures may be based on a combination of Fast Healthcare Interoperability Resources (FHIR) , Consolidated-Clinical Data Architecture (C-CDA) and/or client-specific structure definitions.

Description:

The primary goal of the ASH Registry is to further the scientific knowledge base for the diagnosis, understanding, and management of benign and malignant hematologic conditions by assembling data collected in usual care and clinical trials. Secondary goals are to characterize and study practice patterns for benign and malignant hematologic conditions in usual clinical practice, and to aggregate patient-reported data to further understand and improve the patient experiences of those affected by these conditions. These objectives will be fulfilled by amassing previously collected data within institutions and networks, and by building consortia of institutions and networks to support prospective data collection efforts.

As a research-focused effort, another objective of the ASH Registry is to create a learning community of hematologic researchers and clinicians by inviting collaborative analyses and publications of the data that are collected within it. These analyses may be valuable to basic and translational researchers developing new lines of scientific inquiry; clinical researchers studying the safety and efficacy of hematologic therapies in current practice; industry participants developing new therapies or new indications for previously developed treatments; regulators who are interested in new endpoints and other insights to facilitate the evaluation of novel approaches; and patients who are looking to understand how hematologic diseases and treatments for these diseases will affect their lives. As these different stakeholder groups come together to develop and disseminate these analyses, the ASH Registry will further expand to accommodate additional data collection to address yet unanswered questions that follow.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 20000
• Est. completion date: January 31, 2025
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 65 Years

Eligibility

Inclusion Criteria:

• Patients (>18 years of age) must have diagnostically- or investigator-confirmed benign or malignant hematologic disease.

• For prospective data collection efforts within the ASH Registry that require informed consent, children (<18 years of age) with hematologic disease whose parent/legal guardian consents on their behalf may be included.

Exclusion Criteria:

• Adults that are unable to consent.

• Prisoners

Related Conditions & MeSH terms

• Benign and Malignant Hematologic Diseases
• Hematologic Diseases

Intervention

Combination Product:
• Protease Inhibitors
Nucleic Acid Synthesis Inhibitors,Hydroxyurea,Antineoplastic Agents

Locations

Country	Name	City	State
United States	American Society of Hematology	Washington	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
American Society of Hematology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Minimal Residual Disease	Cancer cells from the bone marrow) that remain in the patient during treatment, or after treatment when the patient is in remission e.g. 3 months, 6 months, one year, or end of current treatment.	Up to 5 Years
Secondary	Patient reported outcomes (health-related QoL )	Health-related QoL	Up to 5 Years